Immusoft announced a research collaboration with Takeda to discover, develop and commercialize transformative cell therapies in rare inherited metabolic disorders with central nervous system (CNS) manifestations and complications using Immusoft’s Immune System Programming (ISP™) technology platform, which modifies a patient’s B cells and instructs the cells to deliver gene-encoded therapies.
The collaboration will focus on delivering protein therapeutics across the blood-brain barrier, a promising area of Immusoft’s research, which has the potential to enable the treatment of diseases with unmet needs.
Under the terms of the agreement, Immusoft will receive an undisclosed upfront payment and research funding support. The company is also eligible to receive future option fees and milestone payments with a total potential value of more than $900 million if all options are exercised and all milestones are achieved over the course of the partnership. Takeda has options to exclusively license the programs at the preclinical stage and Immusoft is eligible for tiered royalties on future products resulting from the partnership. Takeda would be responsible for further preclinical and clinical development, and commercialization.
“We are excited to enter this collaboration with Takeda, a recognized global leader in rare disease therapies,” said Sean Ainsworth, Chief Executive Officer, Immusoft. “This advances our leadership position in B cells as biofactories for therapeutic protein delivery, a novel approach that Immusoft has pioneered. This partnership provides Immusoft with significant resources to further develop our Immune System Programming (ISP™) technology platform, and therapies in diseases for which patients have limited options.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!